EUVIMEDEUVIMED entdecken
Crossref

Outcomes of additional chemotherapy for esophageal squamous cell carcinoma following non-curative endoscopic submucosal dissection

Yujiro Adachi, Yoshito Hayashi, Shinji Yoneda, Ayaka Tajiri, Hiromu Fukuda, Eiji Kimura, Kentaro Nakagawa, Hirotsugu Saiki, Ryotaro Uema, Takeo Yoshihara, Yoshiki Tsujii, Tetsuo Takehara

International Journal of Clinical Oncology · 2025

DOI: 10.1007/s10147-025-02893-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Yujiro Adachi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Endoscopic Mucosal Resection, Esophageal Neoplasms. Die Arbeit nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pathological T1a-muscularis mucosa with lymphovascular invasion and T1b-submucosa are high-risk factors for lymph node metastasis in esophageal squamous cell carcinoma (ESCC). Esophagectomy and chemoradiotherapy are recommended following endoscopic submucosal dissection (ESD) but can lead to complications. Here, we evaluated the efficacy and safety of chemotherapy following ESD. METHODS: This prospective and retrospective study included patients with pathological T1a-muscularis mucosa with lymphovascular invasion or T1b-submucosa who underwent esophageal ESD between June 2006 and August 2023, followed by chemotherapy or chemoradiotherapy. The overall survival, cause-specific survival, recurrence-free survival, hospitalization period, and the occurrence of grade ≥ 3 adverse events were compared between the chemotherapy and chemoradiotherapy groups. RESULTS: The patient and tumor characteristics and pathological findings did not significantly differ between the chemotherapy (n = 16) and chemoradiotherapy (n = 15) groups. The 5-year overall and recurrence-free survival rates were significantly higher in the chemotherapy group than in the chemoradiotherapy group (100.0% vs. 77.8%, P < 0.001 and 92.3% vs. 84.9%, P = 0.007, respectively; log-rank test). The 5-year cause-specific survival rate did not significantly differ between groups (100.0% vs. 83.3%, P = 0.14, log-rank test). The hospitalization period was significantly shorter in the chemotherapy group than in the chemoradiotherapy group (34 vs. 48 days, P < 0.001). Grade ≥ 3 adverse events occurred in 4 (25.0%) and 11 (73.3%) patients in the chemotherapy and chemoradiotherapy groups, respectively. CONCLUSIONS: Chemotherapy is a safe and effective additional treatment for ESCC (pathological T1a-muscularis mucosa with lymphovascular invasion or T1b-submucosa) after ESD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal Squamous Cell CarcinomaEndoscopic Mucosal ResectionEsophageal NeoplasmsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesProspective StudiesChemoradiotherapyTreatment OutcomeEsophagectomyLymphatic MetastasisNeoplasm Recurrence, Local

Stichwörter der Autor:innen

ChemoradiotherapyChemotherapyEndoscopic submucosal dissectionSuperficial esophageal cancer

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
  • Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. y.hayashi@gh.med.osaka-u.ac.jp.
  • Department of Gastroenterology and Hepatology, Ikeda Municipal Hospital, Osaka, Japan.
  • Kansai Rosai Hospital, Hyogo, Japan.

Zitieren

APA

Adachi, Y., Hayashi, Y., Yoneda, S., Tajiri, A., Fukuda, H., Kimura, E., Nakagawa, K., Saiki, H., Uema, R., Yoshihara, T., Tsujii, Y., & Takehara, T. (2025). Outcomes of additional chemotherapy for esophageal squamous cell carcinoma following non-curative endoscopic submucosal dissection. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02893-0

Vancouver

Adachi Y, Hayashi Y, Yoneda S, Tajiri A, Fukuda H, Kimura E, et al. Outcomes of additional chemotherapy for esophageal squamous cell carcinoma following non-curative endoscopic submucosal dissection. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02893-0

BibTeX
@article{Adachi2025,
  author = {Adachi, Yujiro and Hayashi, Yoshito and Yoneda, Shinji and Tajiri, Ayaka and Fukuda, Hiromu and Kimura, Eiji and Nakagawa, Kentaro and Saiki, Hirotsugu and Uema, Ryotaro and Yoshihara, Takeo and Tsujii, Yoshiki and Takehara, Tetsuo},
  title = {Outcomes of additional chemotherapy for esophageal squamous cell carcinoma following non-curative endoscopic submucosal dissection},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1007/s10147-025-02893-0}
}
Kostenlos starten →